Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib with Platinum/Gemcitabine in Advanced Urothelial Carcinoma
NCT05030077Phase 2Unknown
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Oct 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in urothelial carcinoma (UC), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
anlotinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05030077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05030077.